



65 West Watkins Mill Road
Gaithersburg, MD 20878
tel: 240-632-0740
fax: 240-632-0735
www.genvec.com

FOR IMMEDIATE RELEASE:

CONTACT:

Sharon L. Weinstein
Director, Investor Relations
& Corporate Communications
240 632 5511
sweinstein@genvec.com

GENVEC TO PRESENT AT BIO InvestorForum

GAITHERSBURG, MD – October 2, 2007 – GenVec, Inc. (Nasdaq: GNVC) today announced that Paul H. Fischer, Ph.D., President and CEO, will be presenting at the BIO InvestorForum 2007 taking place October 9 – October 11. Dr. Fischer will provide a company overview and update on Wednesday, October 10, 2007 at 11:15 AM PT (2:15 PM ET) at the Palace Hotel in San Francisco, California.

A live webcast of Dr. Fischer’s presentation will be available on the Company’s web site at www.genvec.com and archived for 30 days. To access the webcast or the replay, go to the “Investor Relations” page, and click on the link to the Webcasts and Data section.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product, TNFerade™ is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company’s various filings with the Securities and Exchange Commission.

###